Since TFDP3 is limited to expression in testis and most cancer tissues, including hepatocellular carcinoma, prostate cancer, breast cancer, targeting TFDP3 may provide a novel promising strategy for overcoming chemoresistance in residual cancer, and stop progression to relapse and metastatic disease. This evidence concerns the gene TFDP3 and breast carcinoma.